Skip to main content
Clinical Trials/NCT06330610
NCT06330610
Recruiting
Not Applicable

Evaluation de l'efficacité du Support Nutritionnel entéral Intermittent Sur la défaillance d'Organes de Patients de réanimation Sous Ventilation assistée ENteral NUTrition - Continue Intermittent

University Hospital, Rouen1 site in 1 country174 target enrollmentJuly 9, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Intermittent Fasting
Sponsor
University Hospital, Rouen
Enrollment
174
Locations
1
Primary Endpoint
Evolution of variation of the SOFA (Sepsis-related organ failure assessment) score.
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

This study aims to evaluate the efficiency of intermittent enteral nutrition versus continuous enteral nutrition to prevent from organ failures for patients at the acute phase of sepsis shock with mechanical ventilation in ICU.

Detailed Description

Some pre-clinical and observational studies have suggested that intermittent fasting may have a positive impact on patients in ICU by increasing protein synthesis, sensibility to insulin, cetogenesis, autophagy by respecting the circadian rhythm. This study aims to evaluate the impact on organ failures of an intermittent enteral nutrition versus continuous enteral nutrition in patients at the acute phase of sepsis shock with mechanical ventilation in the ICU.

Registry
clinicaltrials.gov
Start Date
July 9, 2024
End Date
October 9, 2027
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital, Rouen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient admitted in ICU for less than 48h, with invasive mechanical ventilation predicted for at least 48h, that can undergo nasogastric feeding for 7 days.
  • Patient under vasopressive drugs
  • Adult patients (age ≥ 18 years)
  • Informed person who has read and signed their consent
  • If the patient is unable to sign their consent (emergency situation), the consent will be signed by a trusted person or a family member, and consent to continue the study will be requested subsequently.
  • If the patient is unable to sign their consent (emergency situation) and no trusted person is present, the patient may be included in the study. In this case, consent to continue the study will be requested from a trusted person as soon as possible, or from the patient if they are able to understand and sign the consent.
  • Affiliation to a social security scheme
  • No current pregnancy: for women of childbearing age, a beta-HCG blood pregnancy test will be performed upon inclusion; for postmenopausal women, a confirmatory diagnosis must be obtained.

Exclusion Criteria

  • Contraindication to enteral nutrition and/or nasogastric tube insertion: esophageal varices and occlusive syndrome
  • Artificial enteral nutrition that cannot be initiated within 48 hours of intubation
  • Enteral nutrition ongoing for more than one hour at the time of inclusion
  • Need for exclusive or supplemental parenteral nutrition
  • Moribund patient
  • Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/guardianship or curatorship
  • Pregnant or breastfeeding woman

Outcomes

Primary Outcomes

Evolution of variation of the SOFA (Sepsis-related organ failure assessment) score.

Time Frame: day-1 (nutrition start) and day-7

Comparison of variation of the SOFA score between patients with intermittent nutrition versus patients with continuous nutrition.

Secondary Outcomes

  • Evaluation of death(from day 1 to day 90)
  • evaluation of caloric intake(from day-1 (nutrition start) to day-7)
  • evaluation of protein intake(from day-1 (nutrition start) to day-7)
  • Measurement of nutritionnal status(day-1 (nutrition start) and day-7)
  • Evaluation of the digestive tolerance(from day-1 (nutrition start) to day-7)
  • Evaluation of the metabolic response(day 1, day 4 and day 7)
  • Evaluation of quality of life(up to day 90)
  • Evaluation of the nosocomial infections(from day-1 (nutrition start) to day-7)
  • Adverse events(from day-1 (nutrition start) to day-7)
  • Evaluation of the duration of hospitalisation(day 1 to day 90)
  • Evaluation of the intensive care neuromuscular weakness(Up to day 10)

Study Sites (1)

Loading locations...

Similar Trials